Iovance Biotherapeutics
IOVA
122 hedge funds and large institutions have $1.31B invested in Iovance Biotherapeutics in 2018 Q1 according to their latest regulatory filings, with 43 funds opening new positions, 52 increasing their positions, 18 reducing their positions, and 7 closing their positions.
514% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 7
391% more call options, than puts
Call options by funds: $7.71M | Put options by funds: $1.57M
350% more funds holding in top 10
Funds holding in top 10: 2 → 9 (+7)
189% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 18
185% more capital invested
Capital invested by funds: $461M → $1.31B (+$852M)
40% more funds holding
Funds holding: 87 → 122 (+35)
7.58% more ownership
Funds ownership: 79.36% → 86.94% (+7.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
+$45M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
+$42.8M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$34.6M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$26.4M |
| 5 |
MWNA
Marshall Wace North America
New York
|
+$25.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$21.6M |
| 2 |
JP Morgan Chase
New York
|
-$11.4M |
| 3 |
Axa
Paris,
France
|
-$8.85M |
| 4 |
PM
Prosight Management
Dallas,
Texas
|
-$4.5M |
| 5 |
Millennium Management
New York
|
-$2.11M |
IOVA Hedge Fund Activity: Q1 2018 in Review
122 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q1 2018, worth a combined $1.31B — up 185% from $461M a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new IOVA positions and 7 closed out — a net gain of 36 holders — while 52 added to existing stakes and 18 trimmed.
The largest buyer was Consonance Capital Management, adding an estimated $45M. The largest seller was Broadfin Capital, cutting an estimated $21.6M.
- 122 institutional investors held Iovance Biotherapeutics (IOVA) as of Q1 2018, up from 87 in Q4 2017.
- Funds reported $1.31B of Iovance Biotherapeutics stock for Q1 2018, up 185% quarter-over-quarter.
- 43 funds opened new Iovance Biotherapeutics positions in Q1 2018 and 7 closed out, a net change of +36 holders.
- The largest Iovance Biotherapeutics buyer in Q1 2018 was Consonance Capital Management, an estimated $45M added.
- The largest Iovance Biotherapeutics seller in Q1 2018 was Broadfin Capital, an estimated $21.6M sold.
Based on aggregated 13F filings for Q1 2018.